Compare NUVL & W Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | W |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 11.7B |
| IPO Year | 2021 | 2014 |
| Metric | NUVL | W |
|---|---|---|
| Price | $123.60 | $95.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 28 |
| Target Price | ★ $134.75 | $105.82 |
| AVG Volume (30 Days) | ★ 4.2M | 3.5M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.15 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.39 |
| Revenue Next Year | $1,239.49 | $6.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.14 | $53.07 |
| 52 Week High | $123.69 | $119.98 |
| Indicator | NUVL | W |
|---|---|---|
| Relative Strength Index (RSI) | 66.56 | 68.92 |
| Support Level | $98.56 | $94.54 |
| Resistance Level | $123.62 | $108.31 |
| Average True Range (ATR) | 0.21 | 5.34 |
| MACD | -0.05 | 1.21 |
| Stochastic Oscillator | 82.41 | 94.20 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Wayfair engages in e-commerce in the United States (88% of 2025 sales), Canada, the United Kingdom, and Ireland. It's also embarked on expansion into the brick-and-mortar landscape, with 13 stores (excluding outlets) between the AllModern, Birch Lane, Joss & Main, and Wayfair banners. At the end of 2025, the firm offered more than 40 million products from more than 20,000 suppliers under the brands Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. Its offerings include furniture, everyday and seasonal decor, decorative accents, housewares, as well as advertising and logistics services. Wayfair was founded in 2002 and began trading publicly in 2014.